GCM
RIGL icon

Graham Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Graham Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$376K Sell
13,893
-7,074
-34% -$238K 0.01% 719
2025
Q4 		$898K Sell
20,967
-2,518
-11% -$94.9K 0.02% 421
2025
Q3 		$665K Buy
23,485
+6,731
+40% +$201K 0.01% 513
2025
Q2 		$314K Buy
16,754
+1,597
+11% +$30.3K ﹤0.01% 982
2025
Q1 		$273K Buy
15,157
+5,071
+50% +$103K ﹤0.01% 1030
2024
Q4 		$170K Buy
+10,086
New +$193K ﹤0.01% 1103
2024
Q2 		– Sell
-3,662
Closed -$54.2K – 1311
2024
Q1 		$54.2K Sell
3,662
-267
-7% -$3.6K ﹤0.01% 1008
2023
Q4 		$57K Buy
3,929
+921
+31% +$9.42K ﹤0.01% 936
2023
Q3 		$32.5K Sell
3,008
-5,163
-63% -$62.1K ﹤0.01% 972
2023
Q2 		$105K Buy
8,171
+7,040
+622% +$95.2K ﹤0.01% 886
2023
Q1 		$14.9K Buy
+1,131
New +$18K ﹤0.01% 1016
2022
Q4 		– Sell
-93,529
Closed -$1.1M – 1297
2022
Q3 		$1.1M Buy
93,529
+81,364
+669% +$1.1M 0.04% 443
2022
Q2 		$137K Sell
12,165
-16,321
-57% -$328K 0.01% 947
2022
Q1 		$851K Buy
28,486
+20,137
+241% +$545K 0.03% 368
2021
Q4 		$221K Buy
+8,349
New +$252K 0.01% 435

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's RIGL Position: Q1 2026 in Review

Graham Capital Management reduced its Rigel Pharmaceuticals (RIGL) stake by 34% in Q1 2026, selling an estimated $238K and leaving 13,893 shares worth $376K. The position accounts for 0.01% of the portfolio, ranked #719.

Graham Capital Management first reported a position in RIGL in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.1M in Q3 2022. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Graham Capital Management held 13,893 shares of Rigel Pharmaceuticals worth $376K as of Q1 2026.
  • Graham Capital Management sold 7,074 Rigel Pharmaceuticals shares in Q1 2026, an estimated $238K.
  • Rigel Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #719 holding.
  • Graham Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Graham Capital Management's Rigel Pharmaceuticals position peaked at $1.1M in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.